Zanubrutinib is a second-generation Bruton’s tyrosine kinase (BTK) inhibitor used in the treatment of B-cell malignancies such as mantle cell lymphoma, Waldenström’s macroglobulinemia, and chronic lymphocytic leukemia by blocking B-cell receptor signaling and reducing abnormal lymphocyte proliferation. It was developed in the 2010s by BeiGene as part of efforts to create more selective and better-tolerated BTK inhibitors compared to earlier drugs, and it received regulatory approvals in several countries in the late 2010s and early 2020s due to its improved efficacy and safety profile in clinical studies.
Image
